Optiscan Imaging (ASX:OIL) FCF Margin % : -819.82% (As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Optiscan Imaging FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Optiscan Imaging's Free Cash Flow for the six months ended in Dec. 2023 was A$-3.68 Mil. Optiscan Imaging's Revenue for the six months ended in Dec. 2023 was A$0.45 Mil. Therefore, Optiscan Imaging's FCF Margin % for the quarter that ended in Dec. 2023 was -819.82%.

As of today, Optiscan Imaging's current FCF Yield % is -7.95%.

The historical rank and industry rank for Optiscan Imaging's FCF Margin % or its related term are showing as below:

ASX:OIL' s FCF Margin % Range Over the Past 10 Years
Min: -3206.52 Med: -218.77 Max: -118.98
Current: -336.13

During the past 13 years, the highest FCF Margin % of Optiscan Imaging was -118.98%. The lowest was -3206.52%. And the median was -218.77%.

ASX:OIL's FCF Margin % is ranked worse than
98.05% of 2458 companies
in the Hardware industry
Industry Median: 1.505 vs ASX:OIL: -336.13

Optiscan Imaging FCF Margin % Historical Data

The historical data trend for Optiscan Imaging's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Optiscan Imaging FCF Margin % Chart

Optiscan Imaging Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

FCF Margin %

Get a 7-Day Free Trial

-136.85

-118.98

-242.36

-390.72

-195.18

Optiscan Imaging Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-239.57	-574.40	-292.65	-159.71	-819.82

Competitive Comparison of Optiscan Imaging's FCF Margin %

For the Scientific & Technical Instruments subindustry, Optiscan Imaging's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Optiscan Imaging's FCF Margin % Distribution in the Hardware Industry

For the Hardware industry and Technology sector, Optiscan Imaging's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Optiscan Imaging's FCF Margin % falls into.

Optiscan Imaging FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Optiscan Imaging's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-3.279	/	1.68
	=	-195.18 %

Optiscan Imaging's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-3.681	/	0.449
	=	-819.82 %

Optiscan Imaging FCF Margin % Related Terms

Thank you for viewing the detailed overview of Optiscan Imaging's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Optiscan Imaging (ASX:OIL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Technology » Hardware » Optiscan Imaging Ltd (ASX:OIL) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

16 Miles Street, Mulgrave, Melbourne, VIC, AUS, 3170

Website

https://www.optiscan.com

Optiscan Imaging Ltd is engaged in the development, manufacture, and commercialization of endomicroscopic digital imaging technology solutions for medical, translational, and pre-clinical applications. Its technology offers real-time, 3D, in vivo imaging at the single-cell level, in a non-destructive manner that enables clinicians to make immediate informed decisions. Its products include InVivage, ViewnVivo, and Customisation.